Artal Group S.A. lowered its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 30.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,000 shares of the company’s stock after selling 75,000 shares during the period. Artal Group S.A. owned 0.48% of Intellia Therapeutics worth $4,349,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in Intellia Therapeutics in the second quarter valued at approximately $101,000. Bank of Montreal Can boosted its position in Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares in the last quarter. Nationwide Fund Advisors boosted its position in Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares in the last quarter. Nisa Investment Advisors LLC acquired a new stake in Intellia Therapeutics in the second quarter valued at approximately $134,000. Finally, Wells Fargo & Company MN boosted its position in Intellia Therapeutics by 231.7% in the first quarter. Wells Fargo & Company MN now owns 10,945 shares of the company’s stock valued at $154,000 after buying an additional 7,645 shares in the last quarter. Hedge funds and other institutional investors own 48.89% of the company’s stock.
NTLA has been the subject of several analyst reports. Jefferies Group LLC set a $42.00 price target on shares of Intellia Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 31st. Leerink Swann raised their price target on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a research note on Tuesday, October 31st. They noted that the move was a valuation call. Barclays PLC reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. Chardan Capital downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price target for the company. in a research note on Tuesday, August 29th. Finally, ValuEngine raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $30.17.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The firm had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company’s revenue for the quarter was up 49.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.22) earnings per share. sell-side analysts forecast that Intellia Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.
WARNING: “Intellia Therapeutics, Inc. (NTLA) Shares Sold by Artal Group S.A.” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/20/intellia-therapeutics-inc-ntla-shares-sold-by-artal-group-s-a.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
What are top analysts saying about Intellia Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellia Therapeutics Inc. and related companies.